Alpine Partners VI LLC Invests $158,000 in Vivus Inc. (VVUS)
Alpine Partners VI LLC bought a new stake in Vivus Inc. (NASDAQ:VVUS) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 140,800 shares of the biopharmaceutical company’s stock, valued at approximately $158,000.
A number of other large investors have also bought and sold shares of the company. JPMorgan Chase & Co. acquired a new stake in Vivus during the second quarter valued at $101,000. Bank of Montreal Can purchased a new position in Vivus during the second quarter valued at approximately $123,000. Smith Asset Management Group LP raised its position in Vivus by 69.2% in the second quarter. Smith Asset Management Group LP now owns 120,820 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 49,400 shares during the period. LMR Partners LLP purchased a new position in Vivus during the second quarter valued at approximately $154,000. Finally, Laurion Capital Management LP purchased a new position in Vivus during the second quarter valued at approximately $240,000. Hedge funds and other institutional investors own 37.03% of the company’s stock.
Vivus Inc. (NASDAQ:VVUS) opened at 1.11 on Friday. The firm’s market cap is $115.64 million. The company’s 50-day moving average price is $1.09 and its 200-day moving average price is $1.23. Vivus Inc. has a one year low of $0.92 and a one year high of $2.09.
Vivus (NASDAQ:VVUS) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.20. The firm had revenue of $13.77 million for the quarter, compared to the consensus estimate of $19 million. During the same quarter in the prior year, the firm earned ($0.19) earnings per share. The company’s revenue was down 40.1% on a year-over-year basis. On average, analysts anticipate that Vivus Inc. will post ($0.36) EPS for the current year.
Several research analysts have commented on the company. WallachBeth Capital set a $2.80 price target on Vivus and gave the stock a “buy” rating in a research report on Monday, July 25th. Zacks Investment Research raised Vivus from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Tuesday, July 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Vivus currently has an average rating of “Hold” and an average target price of $1.68.
Vivus Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Want to see what other hedge funds are holding VVUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vivus Inc. (NASDAQ:VVUS).
Receive News & Ratings for Vivus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.